Symbol: CIPLA
Month: 2025-03
Start Price: ₹1407.55
End Price: ₹1442.20
12M Return: 2.46%
6M Return: 2.46%
3M Return: 2.46%
Volatility: 0.218
Sharpe Ratio: 1.666
Max Drawdown: -0.054
Peer Correlation (SUNPHARMA): 0.3783
Peer Correlation (DIVISLAB): 0.3944
Peer Correlation (GRASIM): -0.0777
Average Peer Correlation: 0.2317

Generate a short summary and suggest whether to BUY, SELL, or HOLD.

--- LLM Output ---
**Summary:**

CIPLA, a pharmaceutical company, has shown a steady performance over the past 12 months, with a return of 2.46%. The stock has maintained a consistent performance across different time frames, with 6-month and 3-month returns also at 2.46%. The volatility of the stock is relatively low at 0.218, indicating a stable investment. The Sharpe Ratio of 1.666 suggests that the returns are generated with relatively low risk. The maximum drawdown of -0.054 is also manageable. In terms of peer correlation, CIPLA has a moderate correlation with SUNPHARMA and DIVISLAB, but a negative correlation with GRASIM.

**Recommendation:**

Based on the analysis, I would recommend a **BUY** for CIPLA. The stock's consistent performance, low volatility, and attractive Sharpe Ratio make it an attractive investment opportunity. The moderate correlation with peers in the pharmaceutical sector suggests that CIPLA is not overly dependent on industry trends, which reduces the risk of investment. Additionally, the low maximum drawdown indicates that the stock can withstand moderate market fluctuations. Overall, CIPLA appears to be a stable and relatively low-risk investment option with potential for steady returns.